Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246809 | 0.83 | FDPS (0.43) | FDPSSMPD1LMNAGGPS1 | |
| SCHEMBL11511845 | 0.82 | FDPS (0.52) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL6835461 | 0.76 | FDPS (0.39) | FDPSSMPD1LMNAGGPS1 | |
| SCHEMBL11041750 | 0.75 | FDPS (0.38) | FDPSSMPD1LMNAGGPS1LAP3 | |
| SCHEMBL2342024 | 0.74 | FDPS (0.37) | FDPSSMPD1LMNAGGPS1 | |
| SCHEMBL7612809 | 0.74 | FDPS (0.37) | FDPSLMNAGGPS1LAP3 | |
| SCHEMBL6896476 | 0.74 | FDPS (0.54) | FDPSSMPD1PDE3AGGPS1 | |
| SCHEMBL11168978 | 0.74 | FDPS (0.54) | FDPSSMPD1PDE3AGGPS1 | |
| SCHEMBL11474923 | 0.74 | ALDH1A1 (0.38) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL457919 | 0.72 | FDPS (0.64) | FDPSSMPD1PDE3ALMNAADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509537-B9 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060115815-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | FDPS 330/4885SMPD1 47/4885PDE3A 836/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | FDPS 330/4885SMPD1 47/4885PDE3A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.